Background {#Sec1}
==========

Lung protective ventilation and prevention of ventilator-induced lung injury (VILI) are a cornerstone in the management of Acute Respiratory Distress Syndrome (ARDS) \[[@CR1]\]. But implementing these strategies in patients with poor lung compliance can lead to inadequate gas exchange. The use of veno-venous extra corporeal membrane oxygenation (V-V ECMO) to facilitate lung rest and maintain optimal gas exchange has been significantly growing in the past few years \[[@CR2], [@CR3]\].

Prognosis of the underlying disease, timing, quality of life of survivors and the possibility of being lung transplant candidate remain important considerations for patient selection. There are concerns about initiating ECMO support in immunocompromised patients especially those with underlying HIV (Human Immunodeficiency Virus) infection and AIDS (Acquired Immune Deficiency Syndrome) due to poor outcomes \[[@CR4]\]. We report a case of life threatening respiratory failure due to severe Pneumocystis jirovecii infection complicated by pneumomediastinum in a HIV infected patient who was rescued by V-V ECMO.

Case presentation {#Sec2}
=================

A 26 year old male with no significant past medical history presented to the emergency department with complaints of fever, dry cough, difficulty in breathing and chest pain of 15 days duration. Initial assessment showed an averagely built male with body mass index (BMI) 18.8 kg/m^2^ (normal: 18.5-24.9 kg/m^2^), fever (38.9 °C), tachycardia (heart rate 120/min, regular), tachypnea (respiratory rate 35/min), hypoxia (pulse oximetry: 85 % on room air, PaO~2~: 55 mm Hg) and normal blood pressure (126/76 mm Hg). Systemic examination was unremarkable other than reduced air entry at both lung bases. Blood investigations revealed an elevated white cell count of 14.2 x 10^9^/L (normal: 4.5-10 x 10^9^/L), predominantly neutrophilic; serum electrolytes, renal function, liver function, coagulation profile were within normal limits; lactate was 2.2 mmol/L (normal: \<2 mmol/L) and procalcitonin was 0.6 ng/mL (normal: \<0.5 ng/mL). Blood cultures, sputum for gram's stain and nasal swab for viral polymerase chain reaction (PCR) were collected. Chest x-ray showed bilateral middle and lower zone air space opacities (Fig. [1a](#Fig1){ref-type="fig"}). After oxygen supplementation via nasal cannula, fluid resuscitation and empirical antimicrobial therapy (ceftriaxone 2 gm i.v. once daily, azithromycin 500 mg i.v. once daily and oseltamivir 75 mg orally twice daily) patient was stabilized (PaO~2~ 80 mm Hg on oxygen 2 L/min through nasal cannula) and admitted to medical ward.Fig. 1Chest x-ray of patient. **a** On admission: Bilateral middle and lower zone air space opacities with air bronchograms; **b** After application of non-invasive ventilation: Subcutaneous emphysema around neck and axillary region, hyper-lucency around mediastinal structures suggestive of pneumomediastinum and bilateral pulmonary infiltrates. **c** Post endotracheal intubation and ECMO cannulation

Due to worsening of respiratory function (respiratory rate 30/min and PaO~2~ 60 mm Hg on supplemental oxygen 5 L/min through face mask) on the 2^nd^ day post hospitalization, patient was transferred to medical intensive care unit (MICU). Non-invasive ventilation (NIV) via face mask was initiated to improve respiratory parameters and ceftriaxone was escalated to piperacillin/tazobactam 4.5 gm i.v. every 6 h; azithromycin and oseltamivir were continued. Blood and respiratory samples collected initially did not reveal causative organism for pneumonia. Over the next 2 days patient's condition remained steady with single organ (respiratory) failure requiring intermittent NIV (averaging 16 h/day) with oxygen supplement (FiO~2~ 0.5). As the patient was neurologically appropriate and understood his clinical condition, good adherence to NIV was maintained. On Day 4 of ICU admission, patient's respiratory function further deteriorated (respiratory rate 40/min; PaO~2~ 50 mm Hg on FiO~2~ 0.6) and chest x-ray showed subcutaneous emphysema with pneumomediastinum in addition to bilateral pulmonary infiltrates (Fig. [1b](#Fig1){ref-type="fig"}). After detailed discussion with the patient and addressing his concerns, he was intubated and mechanical ventilation was initiated. This was followed by diagnostic bronchoscopy with broncho-alveolar lavage (BAL) fluid collection and CT (computerized tomography) scan of chest which revealed bilateral diffuse ground glass opacity with extensive basal consolidation and pneumomediastinum (Fig. [2](#Fig2){ref-type="fig"}). Bedside trans-thoracic echocardiography showed good left ventricular function and non-dilated right ventricle. Since serial imaging did not show worsening of pneumomediastinum, it was managed conservatively. Despite optimal sedation, analgesia and neuro-muscular paralysis it was not possible to achieve adequate gas exchange with lung protective ventilation and hence, 'Severe Respiratory Failure' team at our institution was consulted.Fig. 2CT scan of patient. **a** At the level of arch of aorta. **b** Lung bases. Shows bilateral diffuse ground glass opacity with extensive basal consolidation. Pneumomediastinum: air in the anterior and superior mediastinum

On evaluation by the Severe Respiratory Failure team (Table [1](#Tab1){ref-type="table"}), tidal volume was decreasing to critical levels (225 mL) trying to achieve safe ventilation pressures, PaO~2~/FiO~2~ was 200 mm Hg on 45 % of FiO~2~ and 10 cm H~2~O of Positive End-Expiratory Pressure (PEEP). As well patient had severe respiratory acidosis with PaCO~2~ of 109 mm Hg and pH 7.01; pulmonary compliance was only 9 ml/cm H~2~O and Murray score was 3. The decision was made to place the patient on V-V ECMO to facilitate lung protective ventilation, prevent progression of pneumomediastinum and improve respiratory acidosis. 25 French drainage cannula was inserted percutaneously into inferior vena cava via left femoral approach and 23 French return cannula was inserted into the inferior vena cava via right femoral approach under fluoroscopy guidance. Post cannulation, ECMO blood flow and sweep flow were titrated to 4 liters/min each in order to achieve optimal gas exchange. Mechanical ventilation was switched to ultra-protective strategy using Pressure Control Ventilation (PCV) with Peak Inspiratory Pressure (PIP) 15 cm H~2~O, PEEP 5 cm H~2~O, respiratory rate 10/min and FiO~2~ 21 %. Patient was anticoagulated with intravenous heparin infusion targeting an APTT of 50-70 s. Cotrimoxazole 250 mg i.v. every 6 h (20 mg/kg/day of Trimethoprim) and prednisone 40 mg twice daily through feeding tube were started after Pneumocystis jirovecii was identified in the broncho-alveolar lavage (BAL) fluid on ECMO day 1. Subsequently, serology confirmed HIV-1 infection with CD4+ cell count of 84/mm^3^ of blood (normal: 600-1500/mm^3^ of blood) and HIV viral load of 907,302 copies/mL. Patient's respiratory parameters progressively improved (Table [1](#Tab1){ref-type="table"}), his blood pressure was maintained without vasopressor support and other organs function including the kidneys remained normal throughout ECMO therapy and ICU stay. Neuro-muscular paralysis was held on ECMO day 2 followed by weaning off sedation on ECMO day 3. The patient was able to tolerate pressure support ventilation (PSV) by ECMO day 4 and he was successfully de-cannulated after 6 days of V-V ECMO support. Patient was extubated the next day, followed by aggressive physiotherapy/mobilization and transfer to medical ward in the next 48 h. There were no complications related to ECMO therapy in this patient during ICU stay and on follow-up post discharge. Patient was explained about his diagnosis and highly active anti-retroviral therapy (HAART: Efavirenz, Emtricitabine and Tenofovir) was initiated in the medical ward. He was discharged in good general condition after 21 days of hospitalization with follow-up appointment in Infectious Disease clinic.Table 1Ventilator and ECMO parametersPre-IntubationPost-IntubationECMO Day 1ECMO Day 2ECMO Day 3ECMO Day 4ECMO Day 5ECMO Day 6Mode of VentilationPSV (NIV)PCVPCVPCVPCVPSVPSVPSVRR4035101010252522PIP1635151515131111PEEP410555333VT-22590200400400360370FiO~2~40 %45 %21 %21 %21 %30 %30 %30 %P/F ratio-200\-\-\-\-\--Blood Flow\--43.783.753.73.63.6Sweep Flow\--42.51.00.500pH7.467.017.447.397.427.477.57.5PaO~2~739083161114707486PaCO~2~44109494345383335*RR* Respiratory rate, *PIP* Peak Inspiratory Pressure (cm H~2~O), *PEEP* Positive End Expiratory Pressure (cm H~2~O), *VT* Tidal volume (mL), *FiO* ~*2*~ Fraction of inspired oxygen (%), *P/F ratio* Ratio of partial pressure arterial oxygen and fraction of inspired oxygen (mm Hg), *PaO* ~*2*~ Partial pressure of oxygen in arterial blood (mm Hg), *PaCO* ~*2*~ Partial pressure of carbon dioxide in arterial blood (mm Hg), *NIV* Non Invasive Ventilation, *PSV* Pressure Support Ventilation, *PCV* Pressure Control Ventilation

Discussion {#Sec3}
==========

The frequency of ICU admission for Pneumocystis pneumonia in immunocompromised patients is decreasing but mortality is high if it progresses to respiratory failure requiring mechanical ventilation \[[@CR5]\]. The most common manifestation on chest radiographs is bilateral interstitial or alveolar opacities. Parenchymal/sub-pleural cysts and pneumatoceles are frequently seen on CT scan. Spontaneous pneumothorax can occur in up to 36 % of patients with Pneumocystis jirovecii pneumonia \[[@CR5], [@CR6]\]. However, spontaneous pneumomediastinum is an uncommon complication with no reported incidence rates. The mechanism of spontaneous pneumomediastinum can be explained by the existence of a decreasing pressure gradient between the alveoli and the lung interstitium that can result in alveolar rupture. This leads to the accumulation of air in the interstitium that circulates centripetally through the venous sheaths to the hilum and mediastinum as the pressure in the mediastinum is lower than that of the lung periphery \[[@CR7]\]. Our patient developed pneumomediastinum while on NIV. Barotrauma is very uncommon and pneumothorax following NIV occurs in less than 5 % of cases \[[@CR8]\]. Development of pneumomediastinum in Pneumocystis jirovecii pneumonia patient receiving NIV has been reported previously \[[@CR9]\]. This could be explained by the rupture of pre-existing pneumatoceles or cysts under the effect of positive pressure ventilation.

Acute respiratory distress syndrome (ARDS) is a life threatening respiratory condition. The Berlin definition classifies ARDS as mild, moderate and severe according to the value of PaO~2~/FiO~2~ ratio (Table [2](#Tab2){ref-type="table"}) \[[@CR10]\]. The main supportive therapy for ARDS is positive pressure mechanical ventilation which helps to ensure adequate oxygenation. A landmark trial conducted in the late 1990s by the ARDS Network compared conventional tidal volume of 12 ml/kg with low tidal volume of 6 ml/kg and permissive hypercapnia. A 9 % absolute mortality reduction was found in the low tidal volume ventilation group. In this study, target tidal volume was calculated based on ideal body weight (IBW) with targeted plateau pressures of \<30 cm H~2~O and permissive hypercapnia \[[@CR1]\]. Our patient did not retain CO~2~ while breathing spontaneously or supported by NIV. But soon after endotracheal intubation and mechanical ventilation he developed severe hypercapnia. This could be explained by the fact that during spontaneous breathing patient was inhaling large tidal volumes which resulted in increased minute ventilation and adequate CO~2~ clearance at the expense of high trans-pulmonary pressures resulting in worsening of air leak. After intubation, sedation and paralysis; lung protective ventilation was provided which resulted in severe (permissive) hypercapnia. Thus, ventilating this patient with ARDS and air leak syndrome was challenging because a balance was to be maintained between providing adequate gas exchange and preventing worsening of pneumomediastinum. The Extracorporeal Life Support Organization (ELSO) guidelines for Adult Respiratory Failure 2013 have listed carbon dioxide retention on mechanical ventilation despite high plateau pressures (\>30 cm H~2~O) and severe air leak syndrome as indications for initiating extracorporeal life support \[[@CR11]\]. Based on these recommendations we provided ECMO therapy to our patient, as a bridge to recovery from severe pulmonary infection.Table 2ARDS Berlin definitionTiming:Within 1 week of a known clinical insult or new or worsening respiratory symptoms.Chest imaging^a^:Bilateral opacities --- not fully explained by effusions, lobar/lung collapse, or nodules.Origin of edema:Respiratory failure not fully explained by cardiac failure or fluid overload.Need objective assessment (e.g., echocardiography) to exclude hydrostatic edema if no risk factor presentOxygenation^b^: • Mild - 200 mm Hg \< PaO~2~/FiO~2~ ≤ 300 mm Hg with PEEP or CPAP ≥5 cm H~2~O^c^ • Moderate - 100 mm Hg \< PaO~2~/FiO~2~ ≤ 200 mm Hg with PEEP ≥5 cm H~2~O • Severe - PaO~2~/FiO~2~ ≤ 100 mm Hg with PEEP ≥5 cm H~2~O*CPAP* continuous positive airway pressure, *FiO* ~*2*~ fraction of inspired oxygen, *PaO* ~*2*~ partial pressure of arterial oxygen, *PEEP* positive end-expiratory pressure^a^Chest radiograph or computed tomography scan^b^If altitude is higher than 1000 m, the correction factor should be calculated as follows: \[PaO~2~/FIO~2~\*(barometric pressure/760)\]^c^This may be delivered noninvasively in the mild acute respiratory distress syndrome group

There are very few case reports of ECMO therapy for severe respiratory failure due to Pneumocystis pneumonia in HIV/AIDS patients (Table [3](#Tab3){ref-type="table"}) \[[@CR9], [@CR12]--[@CR15]\]. All reported patients required V-V ECMO support for primarily respiratory failure other than the case reported by Gutermann et al, who was provided V-A (veno-arterial) ECMO therapy post cardiac arrest. 5 out of 8 patients had concomitant pneumothorax/pneumomediastinum which could have possibly worsened the respiratory failure, necessitating rescue ECMO therapy. The timing for initiation of V-V ECMO in severe respiratory failure remains debatable. However, based on previous studies it has been observed that increased pre-ECMO ventilation duration is associated with worse outcomes \[[@CR16]\]. One of the exclusion criteria in CESAR trial was high pressure (\>30 cm H~2~O of peak inspiratory pressure) and/or high FiO~2~ (\>0.8) ventilation \>7 days \[[@CR2]\]. In our patient the duration of pre-ECMO invasive ventilation was very short and this could be one of the contributing factor for his improved outcome. Fifty percent of the reported cases survived to hospital discharge. It is interesting to note that the patients who survived had a shorter duration of ECMO support (mean 9.25 versus 41 days). Advanced patient age, increased pre-ECMO ventilation duration, diagnosis category and complications while on ECMO are some of the factors associated with adverse outcomes in patients receiving ECMO support \[[@CR17]\].Table 3Adult patients with HIV/AIDS and severe Pneumocystis jirovecii pneumonia requiring ECMO therapyPatient (Ref)Age (years)/Gender (M/F)Pre-ECMO invasive ventilation (days)Pneumothorax/PneumomediastinumPre-ECMO P/F ratio; PaCO~2~; pHECMO ConfigurationDuration of ECMO (days)CD4 count (cells/mm^3^)HIV viral load (copies/mL)Anti-Pneumocystis treatmentTiming of ART initiationOutcomeGutermann et al \[[@CR10]\]55/M4NoNR; NR; NRVeno-arterial4980,235TMP/SMXPost-ECMOSurvived to hospital dischargeSteppan \[[@CR11]\]39/M8YesNR; NR; NRVeno-venous14696297CLI + PI, then ATQ, then TMP/SMXPre-ECMODied on ECMOGoodman et al \[[@CR12]\]25/MNRNo63.6; 52.9; 7.38Veno-venous6936622,234PI, then CLI + PQ, then TMP/SMXPre-ECMODied on ECMOGoodman et al \[[@CR12]\]30/F3Yes50.1; 41.6; 7.39Veno-venous713976,631TMP/SMXPost-ECMOSurvived to hospital dischargeDe Rosa et al \[[@CR13]\]21/FNRYes120; NR; NRVeno-venous202118,330TMP/SMX, then CLI + PQNRSurvived to hospital dischargeDe Rosa et al \[[@CR13]\]24/MNRNo100; NR; NRVeno-venous24350,728TMP/SMX, then CLI + PQ + ATQDuring ECMODied in hospital post ECMOCawcutt et al \[[@CR14]\]45/MNRYes50; NR; NRVeno-venous5733113,000TMP/SMX, CLI, PQPre-ECMODied in hospital post ECMOOur patient26/M1Yes200; 109; 7.01Veno-venous684907,302TMP/SMXPost-ECMOSurvived to hospital discharge*P/F ratio* Ratio of partial pressure arterial oxygen and fraction of inspired oxygen (mm Hg), *PaCO* ~2~ Partial pressure of carbon dioxide in arterial blood (mm Hg), *ART* Antiretroviral therapy, *TMP* Trimethoprim, *SMX* Sulfamethoxazole, *CLI* Clindamycin, *PI* Pentamidine, *ATQ* Atovaquone, *PQ* Primaquine, *NR* Not reported

Patients in need of V-V ECMO support have a high predicted mortality, and implementing an invasive therapy that requires central venous cannulation, systemic anticoagulation, and exposure to an extracorporeal bypass circuit involves substantial risk. The most common complication encountered in ECMO patients is bleeding. Cannula site, surgical site, central nervous system and gastrointestinal bleeding are the most frequent hemorrhagic complications. Infection is also relatively common, with culture proven infections occurring in approximately 20 % of adult respiratory ECMO patients. Mechanical complications such as oxygenator failure, clotting, air in the circuit and tubing rupture are other important considerations \[[@CR18], [@CR19]\].

In the CESAR trial \[[@CR2]\], not all patients transferred to the ECMO center received ECMO therapy. Despite this their outcomes were better than those managed in conventional treatment centers. This highlights the fact that management of patients with severe respiratory failure by a specialized team in units that have an ECMO-based management protocol improves outcome. As such, we have developed a 'Severe Respiratory Failure' team at our hospital that receives referrals from ICUs across the country. Their role is to evaluate and manage patients with life threatening respiratory failure who fail conventional ventilation.

Conclusion {#Sec4}
==========

V-V ECMO was an effective rescue therapy in HIV positive patient with an otherwise fatal respiratory failure due to Pneumocystis pneumonia and air leak syndrome. This case report emphasizes on the fact that the use of ECMO support in HIV/AIDS patient is not always futile and can be considered if the patient has favorable baseline characteristics and the primary problem is respiratory failure that has a reversible etiology. It also highlights the role of ECMO in allowing ultra-protective lung ventilation and preventing ventilator-induced lung injury in patients with poorly compliant lungs.
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